Barely Significant
← all phrases

“borderline significant”

11,410 sentences · 11,410 papers · 14,072 search hits before verification · confirmed specimen

Sighted at

p=0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

borderline significantp = 0.051.0× alphagold
The optimal growth increment model for females were improved by allowing for heterogenous variance between MPAs and control areas (ΔAIC = −3.14), with the variance being higher in the MPAs (18.5) than in control areas (13.6). For males, protection had a borderline significant effect on both skipped moulting ( figure 2 ; LRT: status × TL: L = 3.75, d.f. = 1, p = 0.05) and growth increment ( figure 3 ; LRT: status × TL: L = 4.07, d.f. = 1, p = 0.04).
borderline significantp = 0.051.0× alphagold
Age was significantly positively correlated with ED values of the normal marrow cavity of P1 with DBSCT (Philips) ( p = 0.027, r = 0.36), and the correlation was borderline significant with SSDECT (Canon) ( p = 0.05, r = 0.33).
borderline significantp = 0.051.0× alphagold
Overall, the magnitude of mean change in CD4 + T cell-associated HIV-1 DNA was similar between baseline and all treatment time points with a borderline significant mean change in HIV-1 DNA levels from baseline to treatment week 4 being observed in the primary efficacy population (mean −0.21 log 10 copies/10 6 cells; p = 0.05) but not from baseline to week 12 (mean: −0.17 log 10 copies/10 6 cells; p = 0.13) as shown in Table S3 .
borderline significantp = 0.0501.0× alphagold
The 11 men who had erectile and ejaculatory dysfunction as a plausible escitalopram side-effect had lower mean testosterone (13.8 ± 4.7 nM) and estradiol (0.084 ± 0.023 nM) than the men without the side-effects (19.6 ± 8.7 nM and 0.110 ± 0.034 nM), which was borderline significant for testosterone (Hedges' g = 0.81, t (18.9) = 2.1, p = 0.050) and significant for estradiol using Welch's tests (Hedges' g = 0.86, t (20.9) = 2.2, p = 0.039).
borderline significantp = 0.051.0× alphagold
Moreover, in a prospective randomized, double-blind, placebo-controlled trial enrolling 106 patients with both NAFLD and T2DM who were assigned to receive empagliflozin 10 mg ( n = 35), pioglitazone 30 mg ( n = 34), or placebo ( n = 37) for 24 weeks, only a borderline significant decrease in CAP score was observed with empagliflozin compared with placebo (−29.6 dB/m (−39.5 to −19.6) vs. −16.4 dB/m (−25.0 to −7.8), respectively; p = 0.05) [ 39 ].
borderline significantP = 0.051.0× alphagold
After adjustment for baseline covariate differences, the least square mean change (standard error [SE]) in DSI was borderline significant in the incremental group (− 9.7 [4.8], P = 0.05) and it remained strongly significant in the conventional group (− 13.8 [5.0], P = 0.009).
borderline significantP = 0.0501.0× alphagold
Home O 2 use was borderline significant after adjustment for these additional variables (OR: 1.74; 95% CI: 0.99 - 3.04, P = 0.050.) Figure 1 demonstrates a Kaplan-Meir survival analysis showing a significant increase in all cause mortality in the home O 2 cohort with an overall mean (95% CI) survival time of 6.2 (5.9 - 6.5) years (P < 0.001).
borderline significantp=0.051.0× alphagold
The difference in mean triglyceride level in the placebo group was not significant after the intervention, although there was a borderline significant difference in the intervention group (p=0.05); nevertheless, the changes in mean triglyceride level between the two groups did not indicate a significant difference.